Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim) in 2015, the first biosimilar in the U.S. market, following which biosimilars have been gaining traction in this market as well. For biosimilars to achieve and maintain a strong position in the major pharmaceutical markets, they must earn physicians' trust. By elucidating physicians’ decision-making process in the use of biosimilars versus biologics, clients can learn the most important attributes that a biosimilar should have. Clarivate conducted primary market research in the United States, France, and Germany with physicians from six specialties (gastroenterologists, endocrinologists, nephrologists, rheumatologists, medical oncologists, and hematology-oncologists) to obtain insight into their experiences with and perceptions of biosimilars. In this report, we examine how physicians’ experiences and attitudes compare across specialties and countries and how their views and adoption of biosimilars by patients have evolved over time.
Questions Answered in This Report:
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 547 physicians from six specialties—endocrinologists (93), gastroenterologists (92), nephrologists (90), rheumatologists (90), hematologist-oncologists (92), and medical oncologists (90).